Surf Air Mobility
DevvStream

Arbe Robotics Announces Q2 2024 Financial Results

TEL AVIV, Israel, Aug. 6, 2024 /PRNewswire/ -- Arbe Robotics Ltd. (Nasdaq: ARBE) (TASE: ARBE) ("Arbe"), a global leader in Perception Radar Solutions, today announced financial results for its second quarter, ended June 30, 2024.

Key Q2 and Recent Company Highlights:

  • Arbe's chipset was selected by one of the top ten OEMs worldwide for the development of its next-generation imaging radar aimed at serial production. The selection of Arbe's technology presents a significant commercial opportunity given its applicability across a wide range of vehicle classes.
  • Arbe collaborates with a prominent European truck manufacturer to revolutionize truck safety with Arbe's imaging radar. The manufacturer is set to integrate Arbe's radar into its next-generation sensor suite as part of the transition to an advanced implementation stage.
  • Arbe is actively engaged in achieving four design-ins with leading global automakers. Despite longer decision cycles, Arbe expects those decisions in the coming months.
  • During the second quarter, Arbe participated in the final stages of OEM RFQ processes along with its Tier 1s: Magna, HiRain, Weifu, and Sensrad.
  • The demand for high-channel count solutions is widespread across the board, and Arbe's solution is recognized by leading OEMs as the radar with the largest channel array at the best price per channel.
  • Arbe began trading on the Tel Aviv Stock Exchange (TASE) and issued convertible debentures totaling approximately $30 million to Israeli investors. This strategic move aims to bolster its cash reserves in anticipation of upcoming OEM selections. The proceeds from the debenture offering are held in escrow and will be released upon meeting certain conditions by March 31, 2025. 

"We are excited to announce that we have reached a significant milestone with two key customers. The selection of our imaging radar by both a leading OEM and a prominent European truck manufacturer validates our technology and highlights its market appeal. We are in the final stages of RFPs and RFQs with our Tier 1s, and we believe that we are on track to secure additional major OEM selections this year," said Kobi Marenko, Chief Executive Officer. "Arbe is well-positioned to capitalize on the growing demand for advanced radar systems, and we anticipate an increase in sales and market share in the near future."

Second Quarter 2024 Financial Highlights

Revenues for Q2 2024 were $0.4 million, an increase from $0.3 million in Q2 2023. Backlog as of June 30, 2024, was $0.8 million.

Negative gross margin for Q2 2024 was 9.5%, compared to negative gross margin of 1% in Q2 2023, mainly related to headcount increase.

Operating expenses in Q2 2024 were $11.6 million, compared to $12.6 million in Q2 2023. The decrease in operating expenses was primarily driven by a decrease in R&D materials and to a lesser extent due to a labor cost decrease, partially offset by doubtful debts provision and debt issuance costs. Research and Development decreased, from $9.1 million in Q2 2023 to $7.9 million in Q2 2024, the decrease was mainly related to finalization and maturing stages of production and labor cost savings. Sales and Marketing expenses decreased from $1.5 million in Q2 2023 to $1.4 million in Q2 2024, related to lower travel and conference expenses. General and Administrative expenses increased from $2.0 million in Q2 2023 to $2.3 million in Q2 2024, later include a one-time provision and offering fees.

As a result, our operating loss in Q2 2024 was $11.6 million compared to a $12.6 million loss in Q2 2023.

Net loss in the second quarter of 2024 decreased to $11.8 million, compared to a net loss of $12.6 million in the second quarter of 2023. Net loss in Q2 2024 included $0.1 million of financial expenses, consisting of foreign exchange revaluations offset by interest from deposits.

Adjusted EBITDA, a non-GAAP measurement which excludes expenses for non-cash share-based compensation and for non-recurring items, for Q2 2024, yielded a loss of $7.5 million, compared to a loss of $8.4 million in the second quarter of 2023.

Balance Sheet and Liquidity

As of June 30, 2024, Arbe had $8.8 million in cash and cash equivalents and $17.7 million in short term bank deposits. In June 2024, the Company issued convertible debentures in the principal amount of NIS 110,000,000 (approximately $30 million). The proceeds from the sale of the debentures, which were approximately NIS 112,400,000 (approximately $30.5 million), are held in escrow and will be released to the Company upon meeting certain conditions by March 31, 2025 (these funds are classified as other assets on our balance sheet). The Company has incurred losses from operations since its inception and has negative cash flow from operating activities. Considering management's plans and the forecasted revenue, we will have sufficient funds to finance our operation needs in the foreseeable future.

Outlook

  • Our goal of achieving 4 design-ins with automakers remains unchanged, as we observe continued strong interest in our market-leading offering.
  • We have strengthened our position in all our RFQ engagements, even though the OEMs have shifted their decision timelines from late 2023 to 2024.
  • The 2024 annual revenues are expected to be in line with those of 2023, followed by revenue growth in 2025. These revenue projections are based on our expectation that we will be in full production in the second half of 2024, as well as our decision to exclusively focus on getting our chipset into production.
  • We are committed to maintaining a strong and well-managed balance sheet, focusing on cost-effectiveness and the ability to fund our revenue growth. Adjusted EBITDA for 2024 is projected to be in the range of ($30) million to ($36) million.

Conference Call & Webcast Details

Arbe will host a conference call and webcast today at 8:30 am ET. Speakers will include Kobi Marenko, Chief Executive Officer, Co-Founder and Director, and Karine Pinto-Flomenboim, Chief Financial Officer. The Company encourages participants to pre-register for the conference call here. Callers will receive a unique dial-in upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

The live call may be accessed via:

U.S. Toll Free: 1-844-481-3015
International: 1-412-317-1880
Israel Toll Free: 1-809-212373

A telephonic replay of the conference call will be available until August 20, 2024, following the end of the conference call. To listen to the replay, please dial:

U.S. Toll Free: 1-877-344-7529 
International: 1-412-317-0088
Access ID: 6889354

A live webcast of the call can be accessed here or from Arbe's Investor Relations website at https://ir.arberobotics.com/news/ir-calendar. An archived webcast of the conference call will also be made available on the website following the call.

Arbe (Nasdaq: ARBE) (TASE: ARBE), a global leader in Perception Radar Solutions, is spearheading a radar revolution, enabling truly safe driver-assist systems today while paving the way to full autonomous-driving. Arbe's radar technology is 100 times more detailed than any other radar on the market and is a critical sensor for L2+ and higher autonomy. The company is empowering automakers, Tier-1 suppliers, autonomous ground vehicles, commercial and industrial vehicles, and a wide array of safety applications with advanced sensing and paradigm changing perception. Arbe, a leader in the fast-growing automotive radar market, is based in Tel Aviv, Israel, and has offices in China, Germany, and the United States.

Cautionary Note Regarding Forward-Looking Statements

This press release and the earnings call contains or will contain "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended by the Private Securities Litigation Reform Act of 1995. contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended by the Private Securities Litigation Reform Act of 1995. The words "expect," "believe," "estimate," "intend," "plan," "anticipate," "may," "should," "strategy," "future," "will," "project," "potential" and similar expressions indicate forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These risks and uncertainties include, the effect on the Israeli economy generally and on the Company's business resulting from the terrorism and the hostilities in Israel and with its neighboring countries including the effects of the continuing war with Hamas and any further intensification of hostilities with others, including Iran and Hezbollah, and the effect of the call-up of a significant portion of its working population, including the Company's employees; the effect of any potential boycott both of Israeli products and business and of stocks in Israeli companies; the effect of any downgrading of the Israeli economy and the effect of changes in the exchange rate between the US dollar and the Israeli shekel; the Company's ability to meet the conditions to the release from escrow of the proceeds from its recent sale of convertible debentures; the Company's ability to generate additional OEM selections and substantial orders and the risk and uncertainties described in "Cautionary Note Regarding Forward-Looking Statements," "Item 3. Key Information – D. Risk Factors" and "Item 5. Operating and Financial Review and Prospects" and in the Company's Annual Report on Form 20-F for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (the "SEC") on March 28, 2024, as well as other documents filed by the Company with the SEC. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

Information contained on, or that can be accessed through, the Company's website or any other website or any social media is expressly not incorporated by reference into and is not a part of this press release.

CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)

    
  

 June 30, 2024 

 

December 31, 2023

Current Assets:

 

 (Unaudited) 

 

 (Unaudited) 

Cash and cash equivalents

 

8,840

 

28,587

Restricted cash

 

280

 

163

Short term bank deposits

 

17,683

 

15,402

Trade receivable 

 

694

 

1,258

Other assets

 

30,545

 

-

Prepaid expenses and other receivables

 

1,954

 

2,026

Total current assets

 

59,996

 

47,436

     

Non-Current Assets

    

Operating lease right-of-use assets

 

1,895

 

1,740

Property and equipment, net

 

1,434

 

1,309

Total non-current assets

 

3,329

 

3,049

     

Total assets

 

63,325

 

50,485

     

Current liabilities:

    

Trade payables

 

832

 

1,149

Operating lease liabilities

 

519

 

436

Employees and payroll accruals

 

3,265

 

2,916

Convertible debentures

 

29,982

 

-

Accrued expenses and other payables 

 

1,097

 

1,710

Total current liabilities

 

35,695

 

6,211

     

Long term liabilities

    

Operating lease liabilities

 

1,512

 

1,306

Warrant liabilities

 

607

 

875

Total long-term liabilities

 

2,119

 

2,181

     

SHAREHOLDERS' EQUITY:

    

Ordinary Shares

 

 *) 

 

*)

Additional paid-in capital

 

253,702

 

245,733

Accumulated Deficit

 

(228,191)

 

(203,640)

Total shareholders' equity

 

25,511

 

42,093

     

Total liabilities and shareholders' equity

 

63,325

 

50,485

     

*) Represents less than $1.

    

CONSOLIDATED STATEMENTS OF OPERATIONS

 

(U.S. dollars in thousands, except share and per share data)

     
          
  

 3 Months Ended 

 

3 Months Ended

 

6 Months Ended

 

6 Months Ended

 
  

 June 30, 2024 

 

 June 30, 2023 

 

 June 30, 2024 

 

 June 30, 2023 

 
  

 (Unaudited) 

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

Revenues

 

409

 

289

 

546

 

644

 

Cost of revenues

 

448

 

292

 

851

 

608

 

Gross profit (loss)

 

(39)

 

(3)

 

(305)

 

36

 
          

Operating Expenses:

         

Research and development, net

7,914

 

9,091

 

17,311

 

17,215

 

Sales and marketing

 

1,365

 

1,478

 

2,818

 

2,402

 

General and administrative

 

2,296

 

2,014

 

3,940

 

3,644

 

Total operating expenses

 

11,575

 

12,583

 

24,069

 

23,261

 
          

Operating loss

 

(11,614)

 

(12,586)

 

(24,374)

 

(23,225)

 
          

Financial expenses (income), net

 

132

 

25

 

177

 

(707)

 
          

Net loss

 

(11,746)

 

(12,611)

 

(24,551)

 

-22,518

 
          

Basic net loss per ordinary share 

 

(0.15)

 

(0.19)

 

(0.31)

 

(0.34)

 
          

Weighted-average number of
shares used in computing basic
net loss per ordinary share 

 

80,578,820

 

67,762,711

 

79,377,515

 

66,225,739

 
          

Diluted net loss per ordinary share 

 

(0.19)

 

(0.23)

 

(0.39)

 

(0.39)

 
          

Weighted-average number of
shares used in computing
diluted net loss per ordinary share 

 

64,204,137

 

56,450,209

 

63,390,411

 

58,419,059

 
          
          
          

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(U.S. dollars in thousands)

         
  

 3 Months Ended 

 

3 Months Ended

 

6 Months Ended

 

6 Months Ended

 
  

 June 30, 2024 

 

 June 30, 2023 

 

 June 30, 2024 

 

 June 30, 2023 

 

Cash flows from operating activities:

 

 (Unaudited) 

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

Net Loss 

 

(11,746)

 

(12,611)

 

(24,551)

 

(22,518)

 
          

Adjustments to reconcile loss to net cash used in operating activities:

         

Depreciation

 

147

 

139

 

289

 

276

 

Stock-based compensation

 

3,587

 

3,713

 

7,313

 

5,721

 

Warrants to service providers

 

286

 

157

 

634

 

254

 

Revaluation of warrants and accretion

 

(157)

 

(369)

 

(268)

 

(238)

 

Convertible debentures accretion

 

176

 

-

 

176

 

-

 

Change in operating assets and liabilities:

         

Decrease in trade receivable 

 

162

 

48

 

564

 

162

 

Decrease in prepaid expenses and other receivables 

 

245

 

330

 

72

 

504

 

Increase in other assets 

 

(128)

 

-

 

(128)

 

-

 

Operating lease ROU assets and liabilities, net

 

6

 

(8)

 

135

 

-

 

Decrease in trade payables 

 

(1,039)

 

(1,116)

 

(506)

 

(284)

 

Increase (decrease) in employees and payroll accruals

 

204

 

43

 

349

 

(550)

 

Decrease in accrued expenses and other payables

 

(72)

 

(499)

 

(766)

 

(3,706)

 
          

Net cash used in operating activities

 

(8,328)

 

(10,173)

 

(16,687)

 

(20,379)

 
          

Cash flows from investing activities:

         

Change in bank deposits

 

12,621

 

(25,602)

 

(2,281)

 

(25,202)

 

Purchase of property and equipment

 

(126)

 

(87)

 

(225)

 

(119)

 
          

Net cash provided by (used in) investing activities

 

12,494

 

(25,689)

 

(2,506)

 

(25,321)

 
          

Cash flows from financing activities:

         

Proceeds from issuance of ordinary shares, net of issuance costs 

 

-

 

22,496

 

-

 

22,496

 

Issuance costs related to convertible debentures

 

(459)

 

-

 

(459)

 

-

 

Proceeds from exercise of options

 

22

 

46

 

22

 

606

 
          

Net cash provided by (used in)
financing activities

 

(437)

 

22,542

 

(437)

 

23,102

 
          

Effect of exchange rate fluctuations on cash and cash equivalent

 

80

 

(574)

 

214

 

(66)

 
          

Increase (decrease) in cash, cash equivalents and restricted cash 

 

3,650

 

(12,746)

 

(19,844)

 

(22,532)

 

Cash, cash equivalents and restricted cash at the beginning of period

 

5,391

 

45,037

 

28,750

 

54,315

 
          

Cash, cash equivalents and restricted cash at the end of period

 

9,120

 

31,717

 

9,120

 

31,717

 

RECONCILIATION OF GAAP NET LOSS TO NON-GAAP NET LOSS 

 

(U.S. dollars in thousands, except share and per share data)

         
          
  

 3 Months Ended 

 

3 Months Ended

 

6 Months Ended

 

6 Months Ended

 
  

 June 30, 2024 

 

 June 30, 2023 

 

 June 30, 2024 

 

 June 30, 2023 

 

GAAP net loss attributable to ordinary shareholders

 

(11,746)

 

(12,611)

 

(24,551)

 

(22,518)

 
          

Add:

         

Stock-based compensation

 

3,587

 

3,713

 

7,313

 

5,721

 

Warrants to service providers

 

286

 

157

 

634

 

254

 

Revaluation of warrants and accretion

 

(157)

 

(369)

 

(268)

 

(238)

 

Convertible debentures accretion

 

176

 

-

 

176

 

-

 

Non-recurring expenses related to convertible debentures and ATM

805

 

214

 

805

 

214

 
          

Non-GAAP net loss

 

(7,048)

 

(8,896)

 

(15,890)

 

(16,567)

 
          

Basic Non-GAAP net loss per ordinary share 

 

(0.09)

 

(0.13)

 

(0.20)

 

(0.25)

 
          

Weighted-average number of shares used in computing basic
Non-GAAP net loss per ordinary share

 

80,578,820

 

67,762,711

 

79,377,515

 

66,225,739

 
          

Diluted Non-GAAP net loss per ordinary share 

 

(0.09)

 

(0.16)

 

(0.14)

 

(0.29)

 
          

Weighted-average number of shares used in computing diluted
Non-GAAP net loss per ordinary share 

 

64,204,137

 

56,450,209

 

63,390,411

 

58,419,059

 
          

RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

 

(U.S. dollars in thousands)

         
          
  

 3 Months Ended 

 

3 Months Ended

 

6 Months Ended

 

6 Months Ended

 
  

 June 30, 2024 

 

 June 30, 2023 

 

 June 30, 2024 

 

 June 30, 2023 

 

GAAP net loss attributable to ordinary shareholders

 

(11,746)

 

(12,611)

 

(24,551)

 

(22,518)

 
          

Add:

         

Financial expenses (income), net

 

132

 

25

 

177

 

(707)

 

Depreciation 

 

147

 

139

 

289

 

276

 

Stock-based compensation

 

3,587

 

3,713

 

7,313

 

5,721

 

Warrants to service providers

 

286

 

157

 

634

 

254

 

Non-recurring expenses related to ATM

 

68

 

214

 

68

 

214

 
          

Adjusted EBITDA 

 

(7,526)

 

(8,363)

 

(16,070)

 

(16,760)

 
          

Sign Up To Get Daily Green Stock News In Your Inbox

Please review our Disclaimer and Privacy Policy before subscribing.
Else Nutrition

Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...

CLICK TO LEARN MORE
Graphite One

Leveraging its vertically-integrated approach from mine to material manufacturing, Graphite One intends to produce high-grade anode material for the lithium-ion electric vehicle battery market and energy storage systems...

CLICK TO LEARN MORE

COPYRIGHT ©2022 GREEN STOCK NEWS